Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Drop in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 136,600 shares, a decrease of 27.1% from the August 31st total of 187,300 shares. Based on an average trading volume of 223,500 shares, the short-interest ratio is currently 0.6 days. Currently, 1.6% of the shares of the stock are short sold. Currently, 1.6% of the shares of the stock are short sold. Based on an average trading volume of 223,500 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. AIGH Capital Management LLC grew its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 33.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 974,525 shares of the company’s stock after acquiring an additional 242,370 shares during the period. AIGH Capital Management LLC owned about 9.61% of Biofrontera worth $693,000 as of its most recent SEC filing. 10.08% of the stock is owned by institutional investors and hedge funds.

Biofrontera Price Performance

Shares of BFRI opened at $1.06 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.96 and a debt-to-equity ratio of 8.99. The stock has a market cap of $10.75 million, a PE ratio of -0.47 and a beta of 0.53. Biofrontera has a 12-month low of $0.54 and a 12-month high of $2.22. The business has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $0.81.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). Biofrontera had a negative return on equity of 1,104.09% and a negative net margin of 42.34%.The firm had revenue of $9.03 million for the quarter, compared to the consensus estimate of $8.30 million. Analysts anticipate that Biofrontera will post -3.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Biofrontera in a research report on Saturday, September 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $2.75.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.